(S) -1-Boc-3-Hydroxypiperidine CAS 143900-44-1 Ibrutinib Intermediate Ịdị ọcha>99.0% (GC)

Nkọwa dị mkpirikpi:

Aha Chemical: (S)-1-Boc-3-Hydroxypiperidine

CAS: 143900-44-1

Ịdị ọcha nke Chiral:>99.0% (GC)

Ọcha kemịkalụ:>99.0% (GC)

Ọdịdị: White Powder ma ọ bụ kristal

Ọkara nke Ibrutinib (CAS: 936563-96-1)

Ogo dị elu, mmepụta azụmahịa

E-Mail: alvin@ruifuchem.com

Zitere anyị email

Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Ndị etiti metụtara Ibrutinib:
(S) -1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Njirimara kemịkalụ:

Aha Chemical	(S) -1-Boc-3-Hydroxypiperidine
Ụdị okwu	(S) -1- (tert-Butoxycarbonyl) -3-Hydroxypiperidine;(S)-1-Boc-3-Piperidinol
Nọmba CAS	143900-44-1
Nọmba CAT	RF-CC299
Ọnọdụ Ahịa	Na Akụrụngwa, Ike nrụpụta 20 Tọn/ọnwa
Usoro ihe omimi	C10H19NO3
Ibu molekụla	201.27
Ebe Na-agbaze	52.0 ~ 56.0 ℃
Solubility	Soluble na methanol
Ntụgharị a kapịrị ọnụ [a]20/D	+9.0°~+11.0° (C=1 na Chloroform)
Ụdị	Ruifu Chemical

Nkọwapụta:

Ihe	Nkọwapụta
Ọdịdị	White ntụ ntụ ma ọ bụ kristal
Chiral ịdị ọcha	> 99.5% (GC)
Ịdị ọcha kemịkalụ	> 99.5% (GC)
Mmiri (KF)	≤0.50%
Methanol (GC)	≤50ppm
Ethanol (GC)	≤50ppm
DCM (GC)	≤500ppm
3-Hydroxypiperidine	≤0.10%
3-Hydroxypyridine	≤0.20%
1-Boc-3-Piperidone	≤0.10%
1-Boc-4-Hydroxypiperidine	≤0.10%
1.96 RRT	≤0.20%
Ọdịghị ọcha ọ bụla akọwapụtaghị	≤0.10%
Nlele ọkọlọtọ	Standardkpụrụ ụlọ ọrụ
Ojiji	Ndị n'etiti ọgwụ;Ngwakọta Chiral

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri.

Uru:

Ajụjụ:

Ngwa:

(S) -1-Boc-3-Hydroxypiperidine (CAS: 143900-44-1) bụ etiti chiral dị mkpa maka njikọ nke Ibrutinib (CAS: 936563-96-1).Ibrutinib bụ ụdị Bruton tyrosine kinase (BTK) inhibitor, enwere ike iji ya maka ọgwụgwọ ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) na lymphoma mantle cell (MCL).MCL na CLL bụ nke B-cell na-abụghị Hodgkin's lymphoma, nke siri ike ịgwọ ma dị mfe ịmaliteghachi.Immunotherapy kemịkalụ a na-ahụkarị enweghị ebumnuche, na-emekarị mmeghachi omume ọjọọ 3 ma ọ bụ 4.Ibrutinib na B lymphocytes nwere ike ilekwasị anya na BTK bụ nke dị mkpa maka nhazi, ọdịiche, na nnyefe ozi, na-egbochi ọrụ BTK na-agbanwe agbanwe, na-egbochi mmụba cell tumor na nlanarị nke ọma.Ibrutinib nwere ike itinye uche ngwa ngwa mgbe nchịkwa ọnụ gasịrị, n'oge 1 ~ 2h ruru oke ntinye ọbara, mmeghachi omume ọjọọ bụ otu ma ọ bụ abụọ, ya mere, Ibrutinib ga-aghọ nhọrọ ọhụrụ nke ọgwụgwọ CLL na MCL.